Images List Premium Download Classic

Type 1 Diabetes

Type 1 Diabetes-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Methods and compositions for converting non-endocrine pancreatic tissue into insulin-producing cells
University Of Miami
June 07, 2018 - N°20180155692

Compositions and methods are provided for generating islet-like cell clusters. The methods include culturing a whole non-islet pancreatic cell discard or cells sorted therefrom with an effective amount of a molecule having bone morphogenetic protein (bmp) activity (e.g., a bmp polypeptide).
Inhibition of gliadin peptides
Alba Therapeutics Corporation
May 17, 2018 - N°20180134750

Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided.
Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptide
May 10, 2018 - N°20180125933

Embodiments of the present invention provide for novel therapies, pharmaceutical compositions and methods for insulin independence utilizing a new optimized hamster reg3 gamma peptide, which is new to the art and has not previously been considered for development in the 30 year history since its discovery. Methods, pharmaceutical compositions and therapies novel to the prior art are utilized in this invention ...
Type 1 Diabetes Patent Pack
Download + patent application PDFs
Type 1 Diabetes Patent Applications
Download + Type 1 Diabetes-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Type 1 Diabetes-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Insulin mimotopes and methods of using the same
National Jewish Health
May 03, 2018 - N°20180117124

Methods for inhibiting an autoimmune disease by administering to a subject a therapeutically effective amount of a composition that induces conversion of naive t cells into foxp3+ regulatory t cells to induce immunosuppression in the subject. Methods for detecting in a subject an autoimmune disease or a predisposition to an autoimmune disease, and methods for assessing the efficacy of a ...
Methods and pharmaceutical compositions comprising a sglt2 inhibitor for treating or improving erectile dysfunction
Boehringer Ingelheim International Gmbh
April 19, 2018 - N°20180104268

The invention relates to methods for improving glycemic control and for treating erectile dysfunction in a patient diagnosed with prediabetes, type 1 diabetes mellitus, type 2 diabetes mellitus or metabolic syndrome wherein a sglt2 inhibitor is administered to the patient. Furthermore the invention relates to a method for improving a treatment of erectile dysfunction in a male patient diagnosed with prediabetes, type 1 ...
Antibodies against modified insulin for use in treatment of and assays for diabetes
Queen Mary University Of London
March 08, 2018 - N°20180067125

The present invention provides a method of diagnosing type 1 diabetes (t1d) or latent autoimmune diabetes in adults (lada) in a subject comprising testing a sample from the subject for the presence or absence of antibodies against modified insulin, wherein the presence of antibodies against modified insulin in the sample is indicative of t1d or lada in the subject. ...
Type 1 Diabetes Patent Pack
Download + patent application PDFs
Type 1 Diabetes Patent Applications
Download + Type 1 Diabetes-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Type 1 Diabetes-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Method of treating or ameliorating type 1 diabetes using fgf21
Amgen Inc.
January 04, 2018 - N°20180000898

Methods of treating metabolic diseases and disorders using a fgf21 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 1 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels, diabetic nephropathy, neuropathy, retinopathy, ischemic heart disease, peripheral vascular disease and cerebrovascular disease.
Bicyclic compounds, compositions and medicinal applications thereof
December 21, 2017 - N°20170362225

These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of retinoic acid-related orphan receptor gamma (rorγ) such as inflammatory and/or autoimmune disorder, rheumatoid arthritis, psoriasis, psoriatic arthritis, multiple sclerosis, inflammatory bowel disease, allergic diseases, asthma, copd, cancer, cell proliferation, type 1 diabetes, myasthenia gravis, hematopoetic disfunction, systemic ...
Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapies
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
December 21, 2017 - N°20170360834

The present invention relates to tolerogenic mammalian dendritic cells (idcs) and methods for the production of tolerogenic dcs. In addition, the present invention provides methods for administration of tolerogenic dendritic cells as well as particles containing oligonucleotides to mammalian subjects.
Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
Arena Pharmaceuticals, Inc.
December 21, 2017 - N°20170360730

The present invention relates to amide derivatives of formula (xiiia) and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah); idiopathic pah; familial pah; pah associated with a collagen vascular disease, a congenital heart disease, portal ...
Multi-cbv vaccine for preventing or treating type i diabetes
Vactech Oy
October 05, 2017 - N°20170281748

The invention is directed to a vaccine comprising: i) coxsackie b virus cbv1 and cbv2, and ii) at least one coxsackie b virus selected from cbv3, cbv4, cbv5 and cbv6. The cbvs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus.
Probiotic bifidobacterium adolescentis strains
Chr. Hansen A/s
September 07, 2017 - N°20170252382

The present invention relates to novel isolated strains of bifidobacterium adolescentis which are capable of i) increasing the trans-epithelial electrical resistance (ter) of a caco-2 cell monolayer after 10 h treatment to more than 120% of ter at treatment start, ii) inducing secretion of >200 pg/ml of il-10, and/or iii) inducing an il-10:il-12 ratio>1 when co-incubated ...
Anti-tnf antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
Janssen Biotech, Inc.
August 31, 2017 - N°20170247444

The present invention relates to compositions and methods utilizing anti-tnf antibodies having a heavy chain (hc) comprising seq id no:36 and a light chain (lc) comprising seq id no:37 for use in the treatment or prevention of type i diabetes (t1d).. .
Type 1 Diabetes Patent Pack
Download + patent application PDFs
Type 1 Diabetes Patent Applications
Download + Type 1 Diabetes-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Type 1 Diabetes-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Soluble mediator
The Walter And Eliza Hall Institute Of Medical Research
August 17, 2017 - N°20170232061

The present disclosure relates to a soluble cd52 glycoprotein and its use in treating diseases regulated by effector t-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of cd52, and to diagnostic methods based on the detection of cd52 expression levels in a ...
Drug combinations and methods to stimulate embryonic-like regeneration to treat diabetes and other diseases
University Of Southern California
August 17, 2017 - N°20170232053

Stem cell-based therapies can potentially reverse organ dysfunction and diseases but the removal of impaired tissue and reactivation of the program leading to organ regeneration pose major challenges. In mice, a four-day fasting mimicking diet (fmd) induces a step-wise expression of sox17 and pdx-1, resembling that observed during pancreatic development and followed by ngn3-driven generation of insulin-producing β...
Use of dehydroeburicoic acid from antrodia camphorata in the treatment or prevention of diabetes and ...
August 03, 2017 - N°20170216384

The present invention provides a method for treating type 1 diabetes, hyperlipidemia or hepatic lipid accumulation by using dehydroeburicoic acid, as well as a method for decreasing levels of blood glucose, plasma total cholesterol, and triglyceride, and increasing insulin levels; and a method for decreasing hepatic balloon degeneration; and increasing expression levels of membrane glut4 and phospho-akt in myotubes; and enhancing ...
A combination of kynurenine and antigen presenting cells (apc) as therapeutics and methods for their ...
The University Of British Columbia
July 27, 2017 - N°20170209401

This invention provides combinations of kynurenine and antigen presenting cells (apc) for modulating immune tolerance, wherein the combinations may be used to modulate an autoimmune response, which may be of use in the treatment of type 1 diabetes (t1d) or alopecia areata (aa). Uses of kynurenine and antigen presenting cells (apc) as an immune modulator for the treatment of t1...
Small molecule inhibitors of stat3 with anti-tumor activity
University Of Central Florida Research Foundation.
July 20, 2017 - N°20170202795

The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of stat3 signaling, stat3 dimerization, stat3-dna binding, stat5-dna binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but ...
Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
Boehringer Ingelheim International Gmbh
July 06, 2017 - N°20170189437

The present invention is directed to a pharmaceutical composition comprised of one or more sglt-2 inhibitor compound(s) in combination with one or more therapeutic agents which is suitable for the treatment of metabolic disorders including type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, hyperglycemia, postprandial hyperglycemia, overweight, obesity, including class i obesity, class ii obesity, class iii obesity, ...
Novel combination of naturally occurring compounds to assist with suspected mycobacterial infections related to autoimmune ...
June 22, 2017 - N°20170173059

The novel aspect of this invention is that it is a unique formulation of naturally occurring compounds with a unique intention to assist the concerns associated with autoimmune conditions, mainly inflammatory bowel disease (collectively crohn's, ulcerative colitis, irritable bowel syndrome), type 1 diabetes, multiple sclerosis, psoriasis and the suspected infection of the pathogen mycobacterium avium sub-species paratuberculosis (map). Furthermore, its intent ...
Antidiabetic medications
Boehringer Ingelheim International Gmbh
June 22, 2017 - N°20170173027

Methods of using antidiabetic medications which are suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, and hyperglycemia, among others.. .
Loading